International Journal of Clinical Oncology

, Volume 14, Issue 6, pp 485–489

Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data

Review Article

DOI: 10.1007/s10147-009-0942-z

Cite this article as:
Moroi, Y. Int J Clin Oncol (2009) 14: 485. doi:10.1007/s10147-009-0942-z


The notion of sentinel lymph node (SLN) mapping and its use during surgery for staging cancer was initially reported in 1992, in a study involving patients with malignant melanoma. To date SLN biopsy (SLNB) has emerged as a rational approach for staging regional lymph nodes in patients with clinically node-negative melanoma (stage I and II disease). The significance of SLNB as a staging and prognostic tool in melanoma is widely accepted. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the SLN remains very controversial. Whether SLNB improves survival in melanoma patients remains an open question.

Key words

Melanoma Sentinel lymph node biopsy Lymph node dissection Staging tool Prognostic value Therapeutic effect 

Copyright information

© Japan Society of Clinical Oncology 2009

Authors and Affiliations

  1. 1.Department of Dermatology, Graduate School of Medical ScienceKyushu UniversityFukuokaJapan

Personalised recommendations